

**REMARKS**

It is respectfully asserted that the sequence disclosure contained in the application now fully complies with the requirements set forth in 37 C.F.R. § 1.821 to § 1.825. Accordingly, reconsideration and withdrawal of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures ("Notice to Comply") is respectfully requested.

A copy of the Notice to Comply, a paper-copy of the Sequence Listing, and a computer readable form (floppy disk) of the Sequence Listing are enclosed. The Statements required by 37 C.F.R. §1.821(f) and (g) are set forth below.


Pursuant to 37 C.F.R. §1.821 (g), the undersigned attorney of record hereby states that this submission, filed in accordance with 37 C.F.R. §1.821 (g), does not contain new matter.

Pursuant to 37 C.F.R. §1.821 (f), the undersigned attorney hereby states that the content of the paper and computer readable copies of the Sequence Listing submitted in accordance with 37 C.F.R. §1.821 (c) and (e), respectively, are the same.

These amendments are introduced merely to place the sequence listing in the application, (after the specification and before the claims). In view of the amendments, remarks and enclosures, the application complies with the requirements for computer readable disclosure of the biological sequences under 37 C.F.R. §1.821-1.825. Reconsideration and withdrawal of the Notice to Comply is earnestly solicited. The Commissioner is authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0320.

Respectfully submitted,  
FROMMER LAWRENCE & HAUG LLP

By:



Thomas J. Kowalski  
Reg. No. 32,147  
(212) 588-0800

Enclosures: Paper and Disk Sequence Listing;  
Copy of Raw error report; and  
Return receipt postcard.